Monoclonal antibody · developed by Vir Biotechnology
Tobevibart (VIR-3434) is an antibody given by subcutaneous injection.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT07128550 | Phase 3 | Viral Hepatitis | Active not recruiting | VIR |
| NCT05461170 | Phase 2 | Hepatitis D, Chronic | Active not recruiting | VIR |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Hepatitis D, ChronicViral Hepatitis
Updated Nov 1, 2026. Something wrong or missing? Report it on the VIR page.
See VIR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
VIR catalysts and pipeline →